Výsledky vyhledávání - "C. Madroñal"

Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer

Autor: J. Belon, J. Janáriz, M. González Barón, M. de la Puente, Enrique Espinosa, J. Lizón, J. A. Moreno, P. Borrega, C. Madroñal, Ana María Moure Casas, Serafin Morales, J. A. Illarramendi, Ignacio Machengs, T. Checa, J. R. Mel

Publikováno v: Cancer Chemotherapy and Pharmacology. 54:546-552

Epirubicin and docetaxel are two of the most active drugs against breast carcinoma. As the achievement of a pathological complete response (pCR) is important for survival of patients with locally advanced disease, we used both drugs as neoadjuvant ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1757436474779c9120339982fe2fd6d6
https://doi.org/10.1007/s00280-004-0830-1

Zobrazit plný text záznamu

Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer

Autor: A. Rodríguez-Jaráiz, G. Martín, Jaime Feliu, Anna Sundlöv, C. Belda, Javier de Castro, M. Lomas, Enrique Casado, Manuel González-Barón, C. Madroñal, A. Galan

Publikováno v: Cancer chemotherapy and pharmacology. 58(4)

Purpose: To evaluate the feasibility, toxicity and efficacy of the combination of docetaxel and mitomycin C as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Patients and methods: Thirty-eight patients with his

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::794d26d634bab686d94f96c9e752a125
https://pubmed.ncbi.nlm.nih.gov/16555090

Zobrazit plný text záznamu

Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer

Autor: M. J. García, J. Aguiar, C. Madroñal, J. J. Sánchez, Jose Ignacio Chacon, Javier Castro de Carpeño, M. González Barón, A. Colmenarejo, Amalio Ordóñez, J. Feliu

Publikováno v: Cancer chemotherapy and pharmacology. 58(2)

Purpose: Improving chemotherapeutic efficacy in non-small cell lung cancer (NSCLC) will require the development of new strategies to better use currently available agents. To assess the efficacy and safety of a biweekly regimen of cisplatin, gemcitab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87dadb07a2d26b031850855b97fffd57
https://pubmed.ncbi.nlm.nih.gov/16308698

Zobrazit plný text záznamu

Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma

Autor: M. González Barón, Enrique Casado, J. de Castro, Serafin Morales, C. Madroñal, Aurelio Lorenzo, J. Belon, P. M. Gallurt, J. Lizón, J. Dorta, J. Feliu

Publikováno v: Cancer chemotherapy and pharmacology. 55(2)

To evaluate the efficacy and toxicity profile of the combination of docetaxel and prolonged gemcitabine infusion in front-line chemonaive patients with advanced non-small-cell lung cancer (NSCLC).A total of 50 chemonaive patients diagnosed with advan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62378d09ab11922d0ec7bc5bb1fbde40
https://pubmed.ncbi.nlm.nih.gov/15322824

Zobrazit plný text záznamu

Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer

Autor: A. Rodríguez, Jaime Feliu, M. Bolaño, A. Rodríguez-Jaráiz, T. Checa, G. Martín, Javier de Castro, Enrique Casado, Manuel González-Barón, C. Madroñal

Publikováno v: Cancer chemotherapy and pharmacology. 52(3)

To evaluate the feasibility, toxicity and efficacy of the combination of low-dose cisplatin (CDDP) and gemcitabine (GEM) in elderly patients with advanced non-small-cell lung cancer (NSCLC).This phase II trial included 46 patients aged 70 years or ol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26807e27ba26b3c66d4f2cbf45e6d46b
https://pubmed.ncbi.nlm.nih.gov/12783203

Zobrazit plný text záznamu

Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’

Autor: Jaime Feliu, M Gil, Manuel González-Barón, Rafael López, A Llombart, F. Losa, C. Madroñal, Pilar Escudero, Carlos Bosch, C. García-Girón, Maria Jose Safont, J Castro-Carpeño, M. Bolaños, Antonieta Salud

Publikováno v: British Journal of Cancer
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Recercat. Dipósit de la Recerca de Catalunya

BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were asse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86f77f67dbc2da6d043939b20f1dd9cd
https://doi.org/10.1038/sj.bjc.6606037

Zobrazit plný text záznamu

Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group

Autor: J, Feliu, L, López Gómez, C, Madroñal, E, Espinosa, J, Espinosa, C G, Girón, B, Martínez, J, Castro, I, De la Gándara, M G, Barón

Publikováno v: Cancer. 86(8)

Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients. Recent reports indicate that single agent therapy wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d3f0e6100be3e6adaa031ceecc81511a
https://pubmed.ncbi.nlm.nih.gov/10526274

Zobrazit plný text záznamu

Phase II study to evaluate the efficacy of capecitabine combined with bevacizumab as first-line treatment in elderly patients with advanced or metastatic colorectal adenocarcinoma

Autor: Pilar Escudero, Carlos Bosch, Rafael López, Antonieta Salud, J. Feliu, M.J. Safont, Carlos García-Girón, Ferran Losa, C. Madroñal, Manuel González-Barón

Publikováno v: Journal of Clinical Oncology. 27:4119-4119

4119 Background: Colorectal adenocarcinoma is the most common cancer in subjects over 70 years old. New therapies have been developed but limited data about their activity are available in elderly population. Results obtained with capecitabine have s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f8e607871e2ca61c208bb24f075e76c2
https://doi.org/10.1200/jco.2009.27.15_suppl.4119

Zobrazit plný text záznamu

Biweekly nonpegylated liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II-III breast cancer

Autor: M. Centelles, C. Diego, J. M. García, C. Madroñal, Jose I. Mayordomo, P. Puerto, Isabel Alvarez, A. Modolell, M. A. Burillo-R Andres, J. Janariz

Publikováno v: Journal of Clinical Oncology. 25:11049-11049

11049 Background: We have previously reported (ASCO 2006) the efficacy and toxicity of 4 courses of M (75mg/m2) and T (75mg/m2) with G-CSF support in a 21 day schedule as neoadjuvant treatment in patients with resectable breast cancer. Aim: To evalua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3326830a79449e7430a32d8e416ef4c2
https://doi.org/10.1200/jco.2007.25.18_suppl.11049

Zobrazit plný text záznamu

A randomized, phase II trial comparing sequential paclitaxel/cisplatin/gemcitabine/vinorelbine/ (PCGV) with cisplatin/gemcitabine/vinorelbine/ (CGV) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Autor: J. Feliu, Cristobal Belda-Iniesta, C. Madroñal, Manuel González-Barón, Carlos Poblete Jara, G. Martin, J. de Castro, E. Casado Saenz, J. C. Torrego, María Sereno, J. I. Chacón

Publikováno v: Journal of Clinical Oncology. 24:17008-17008

17008 Background: New effective therapies are needed to improve the outcome of patients with advanced NSCLC. In this regard, new approaches such as cisplatin-based triplets have been explored with promising results but high toxicity. Furthermore, seq

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12a5919161d99ad21f4b89acfa122bc1
https://doi.org/10.1200/jco.2006.24.18_suppl.17008

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání